Recital 5, Regulation (EU) 2024/3169

In forcesince 18 Dec 2024

Upon request from a health technology developer, joint scientific consultations on medicinal products may take place in parallel with the scientific advice on medicinal products by the European Medicines Agency pursuant to Article 57(1), point (n), of Regulation (EC) No 726/2004 of the European Parliament and of the Council [Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1, ELI: http://data.europa.eu/eli/reg/2004/726/oj).] (‘scientific advice’). In order for the subgroup on joint scientific consultations of the Coordination Group (‘JSC Subgroup’) to be able to identify the requests for joint scientific consultation to be conducted in parallel with the scientific advice, the health technology developer should indicate in the request for joint scientific consultation whether, in parallel, it is requesting scientific advice from the European Medicines Agency.